StockStory.org on MSN3d
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. Supernus Pharmaceuticals beat ...
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults with treatment-resistant depression ...
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are ...
Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional ...
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback